Your browser doesn't support javascript.
loading
Uncovering a membrane-distal conformation of KRAS available to recruit RAF to the plasma membrane.
Van, Que N; López, Cesar A; Tonelli, Marco; Taylor, Troy; Niu, Ben; Stanley, Christopher B; Bhowmik, Debsindhu; Tran, Timothy H; Frank, Peter H; Messing, Simon; Alexander, Patrick; Scott, Daniel; Ye, Xiaoying; Drew, Matt; Chertov, Oleg; Lösche, Mathias; Ramanathan, Arvind; Gross, Michael L; Hengartner, Nicolas W; Westler, William M; Markley, John L; Simanshu, Dhirendra K; Nissley, Dwight V; Gillette, William K; Esposito, Dominic; McCormick, Frank; Gnanakaran, S; Heinrich, Frank; Stephen, Andrew G.
Afiliación
  • Van QN; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.
  • López CA; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545.
  • Tonelli M; National Magnetic Resonance Facility at Madison, Biochemistry Department, University of Wisconsin-Madison, Madison, WI 53706.
  • Taylor T; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.
  • Niu B; National Mass Spectrometry Resource, Department of Chemistry, Washington University in St. Louis, St. Louis, MO 63130.
  • Stanley CB; Computational Sciences and Engineering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831.
  • Bhowmik D; Computational Sciences and Engineering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831.
  • Tran TH; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.
  • Frank PH; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.
  • Messing S; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.
  • Alexander P; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.
  • Scott D; Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213.
  • Ye X; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.
  • Drew M; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.
  • Chertov O; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.
  • Lösche M; Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213.
  • Ramanathan A; Department of Physics, Carnegie Mellon University, Pittsburgh, PA 15213.
  • Gross ML; Center for Neutron Research, National Institute of Standards and Technology, Gaithersburg, MD 20899.
  • Hengartner NW; Data Science and Learning Division, Argonne National Laboratory, Lemont, IL 60439.
  • Westler WM; National Mass Spectrometry Resource, Department of Chemistry, Washington University in St. Louis, St. Louis, MO 63130.
  • Markley JL; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545.
  • Simanshu DK; National Magnetic Resonance Facility at Madison, Biochemistry Department, University of Wisconsin-Madison, Madison, WI 53706.
  • Nissley DV; National Magnetic Resonance Facility at Madison, Biochemistry Department, University of Wisconsin-Madison, Madison, WI 53706.
  • Gillette WK; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.
  • Esposito D; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.
  • McCormick F; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.
  • Gnanakaran S; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.
  • Heinrich F; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702; frank.mccormick@ucsf.edu stephena@mail.nih.gov.
  • Stephen AG; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545.
Proc Natl Acad Sci U S A ; 117(39): 24258-24268, 2020 09 29.
Article en En | MEDLINE | ID: mdl-32913056
ABSTRACT
The small GTPase KRAS is localized at the plasma membrane where it functions as a molecular switch, coupling extracellular growth factor stimulation to intracellular signaling networks. In this process, KRAS recruits effectors, such as RAF kinase, to the plasma membrane where they are activated by a series of complex molecular steps. Defining the membrane-bound state of KRAS is fundamental to understanding the activation of RAF kinase and in evaluating novel therapeutic opportunities for the inhibition of oncogenic KRAS-mediated signaling. We combined multiple biophysical measurements and computational methodologies to generate a consensus model for authentically processed, membrane-anchored KRAS. In contrast to the two membrane-proximal conformations previously reported, we identify a third significantly populated state using a combination of neutron reflectivity, fast photochemical oxidation of proteins (FPOP), and NMR. In this highly populated state, which we refer to as "membrane-distal" and estimate to comprise ∼90% of the ensemble, the G-domain does not directly contact the membrane but is tethered via its C-terminal hypervariable region and carboxymethylated farnesyl moiety, as shown by FPOP. Subsequent interaction of the RAF1 RAS binding domain with KRAS does not significantly change G-domain configurations on the membrane but affects their relative populations. Overall, our results are consistent with a directional fly-casting mechanism for KRAS, in which the membrane-distal state of the G-domain can effectively recruit RAF kinase from the cytoplasm for activation at the membrane.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas p21(ras) / Quinasas raf Tipo de estudio: Prognostic_studies Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas p21(ras) / Quinasas raf Tipo de estudio: Prognostic_studies Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2020 Tipo del documento: Article